on DBV TECHNOLOGIES (EPA:DBV)
DBV Technologies to Present at Goldman Sachs Healthcare Conference
DBV Technologies, a biopharmaceutical company, has announced its participation in the upcoming Goldman Sachs 47th Annual Global Healthcare Conference. The event, scheduled for June 9, 2026, in Miami, Florida, will feature a fireside chat with Daniel Tassé, the company's CEO. The session will begin at 9:20 AM ET and will be accessible via a live webcast, available on the company's investor website.
DBV Technologies specializes in developing treatments for food allergies and related immunologic conditions. The company focuses on leveraging its proprietary VIASKIN® patch technology, which aims to desensitize the immune system to allergens through epicutaneous immunotherapy (EPIT). This non-invasive method introduces microgram amounts of allergens via the skin to build tolerance.
R. P.
Copyright © 2026 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all DBV TECHNOLOGIES news